Concr is a techbio company providing predictive modelling solutions to enhance confidence and foresight about therapeutic efficacy of existing and emerging cancer drugs. By accurately predicting response for individual patients and cohorts, we enable more efficacious and informative trials, thereby improving probability of success of novel cancer therapeutics.
Our Farr-Sight® platform, built on decades of astrophysics research, models diverse data interactions to simulate human disease biology, enabling accurate predictions with minimal data. This is especially valuable in early-stage trials and rare cancers.
Validated through collaborations with Roche, Step Pharma, The Institute of Cancer Research, The Christie NHS Foundation Trust, Durham University, and The University of Queensland, our solutions are trusted by researchers in industry, academia and healthcare.
Concr’s investors include the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Debiopharm, Cambridge Angels, Parkwalk Advisors, Deep Science Ventures and SyndicateRoom. The company has also received a grant from Innovate UK to trial Concr’s technology for improving treatment decision-making in clinic. The company’s HQ is in London, England, with a wholly owned subsidiary in Brisbane, Australia.
Company Details
- Employees
- 9
- Founded
- -
- Address
- London, England, Gb
- in****@****oncr.co
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- concr.co
- Keywords
- Biotechnology, Precision Medicine, Oncology Research, Drug Development, Machine Learning, Statistical Modelling.
- HQ
- London, England
Concr Questions
Concr's website is concr.co
Concr's LinkedIn profile is https://uk.linkedin.com/company/concr
Concr has
9 employees.
View email and phone details for 9
employees at Concr.
Concr's industry is
Biotechnology Research
Concr's top competitors are
Verve Ventures Vc,
Astex Pharmaceuticals,
Phoremost Ltd,
Biomodal,
52north - Creators Of Neutrocheck®,
T-Therapeutics Ltd,
Pharmenable Therapeutics,
Verinnogen,
Storm Therapeutics Limited,
Spirea.
Concr's support email address is info@concr.co
Concr's categories are Biotechnology Research
Concr's founding year is 2018
